Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Apr 1, 2025
Distillery Therapeutics
Novel brain-regulating peptide hormone BRP for obesity
BioCentury | Apr 1, 2025
Deals
Novo, Merck each pay $200M for pipeline additions: Deals Report
Pharmas enter nine-figure upfront deals in metabolic, cardiovascular areas; plus, Bluebird will consider competing buyout offer
BioCentury | Apr 1, 2025
Product Development
Oral PCSK9 inhibition: Will co-formulation drive success?
AZ’s latest data position AZD0780 as slightly less effective but more convenient than PCSK9 competition
BioCentury | Mar 25, 2025
Finance
Sofinnova’s ‘pan-European’ play, China innovation and Trump’s tariff threat — a BioCentury podcast
How Biovelocita became the largest life sciences accelerator in Europe, the latest at FDA and more
BioCentury | Mar 25, 2025
Deals
Novo buys into obesity triple mechanism; AZ deepens China ties: Deals Report
Plus: Dren Bio strikes $600M bispecific agreement with Sanofi, and more
BioCentury | Mar 12, 2025
Deals
Chasing amylin: Must-have obesity target key to Roche-Zealand deal
Swiss pharma pays $1.7B upfront for Zealand’s petrelintide, adding obesity’s hottest target
BioCentury | Mar 12, 2025
Product Development
Oral peptide win for Protagonist/J&J, Beam’s base editor POC, and more: Clinical Report
Protagonist data led to week’s biggest share price gain, while Arvinas saw biggest loss: in BioCentury’s latest Clinical Report
BioCentury | Mar 11, 2025
Politics, Policy & Law
Makary’s FDA agenda, amylin in obesity and life after DEI
Pending confirmation for new head of FDA will cap a tumultuous transition
BioCentury | Mar 7, 2025
Product Development
Could amylin outshine GLP-1 in obesity?
If the preclinical data translate to the clinic, amylin has a good chance to supplant GLP-1 for the overweight to moderate obesity population
BioCentury | Mar 5, 2025
Data Byte
GLP-1 boom: no signs of slowing as sales continued to surge in 4Q24
Sales of top brands from both Lilly and Novo recorded all-time highs, again
Items per page:
1 - 10 of 1053